title: [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
abstract: OBJECTIVE
  Stage IV melanoma patients with a very advanced disease are usually excluded from clinical trials. We treated 25 stage IV patients with temozolomide - a cytostatic drug with 100% oral bioavailability and considerable penetration of CNS tissue.
  
  
  METHODS
  25 patients (17 female, 8 male) between 24 and 82 years (mean: 55.5 years) were included in this retrospective study. 19 patients had received at least one and up to four previous chemotherapy regimens during the course of stage IV disease. 11 (44%) patients showed cerebral metastases prior to therapy with temozolomide. 200 mg/m2 temozolomide were given orally at home on day 1 to 5 in week 1 and in week 5, respectively.
  
  
  RESULTS
  Out of 23 evaluable patients 2 (8.7%) showed a partial remission, 2 (8,7%) a minor response, 6 (26.1%) had stable disease, 1 (4,3%) a mixed response, and 12 (52.1%) patients experienced disease progression. Sites of remission included brain, lung, liver, lymph nodes and muscle. Two patients interrupted therapy due to severe leuko- and thrombocytopenia (WHO grade 3 and 4). All other patients tolerated treatment with temozolomide well and no dose reduction was necessary. The median overall survival was 7 months (2-28+ months) since beginning of therapy and 15 months (4-63+ months) since onset of stage IV disease.
  
  
  CONCLUSIONS
  Temozolomide represents a safe treatment option in patients with metastatic melanoma and poor prognosis.
authors.affiliation: Klinik für Dermatologie, Venerologie und Allergologie der Christian-Albrechts-Universität zu Kiel, Germany. seiling@dermatology.uni-kiel.de
authors.forename: S
authors.initials: S
authors.lastname: Frick
authors.forename: S
authors.initials: S
authors.lastname: Lischner
authors.forename: F
authors.initials: F
authors.lastname: Rosien
authors.forename: T C
authors.initials: TC
authors.lastname: Haacke
authors.forename: F
authors.initials: F
authors.lastname: Schäfer
authors.forename: E
authors.initials: E
authors.lastname: Christophers
authors.forename: A
authors.initials: A
authors.lastname: Hauschild
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality; D000077204:Temozolomide; D013997:Time Factors
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide